471 related articles for article (PubMed ID: 20427771)
1. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
2. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
4. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
5. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
7. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.
Mehrotra S; Al-Khami AA; Klarquist J; Husain S; Naga O; Eby JM; Murali AK; Lyons GE; Li M; Spivey ND; Norell H; Martins da Palma T; Onicescu G; Diaz-Montero CM; Garrett-Mayer E; Cole DJ; Le Poole IC; Nishimura MI
J Immunol; 2012 Aug; 189(4):1627-38. PubMed ID: 22798675
[TBL] [Abstract][Full Text] [Related]
8. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
9. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
10. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
Clay TM; Custer MC; Spiess PJ; Nishimura MI
Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
[TBL] [Abstract][Full Text] [Related]
11. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.
Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI
J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155
[TBL] [Abstract][Full Text] [Related]
12. MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.
Soto CM; Stone JD; Chervin AS; Engels B; Schreiber H; Roy EJ; Kranz DM
Cancer Immunol Immunother; 2013 Feb; 62(2):359-69. PubMed ID: 22926060
[TBL] [Abstract][Full Text] [Related]
13. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.
Zhao Y; Zheng Z; Robbins PF; Khong HT; Rosenberg SA; Morgan RA
J Immunol; 2005 Apr; 174(7):4415-23. PubMed ID: 15778407
[TBL] [Abstract][Full Text] [Related]
14. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
15. Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.
Cohen CJ; Zheng Z; Bray R; Zhao Y; Sherman LA; Rosenberg SA; Morgan RA
J Immunol; 2005 Nov; 175(9):5799-808. PubMed ID: 16237072
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
17. Requirements for effective antitumor responses of TCR transduced T cells.
de Witte MA; Jorritsma A; Kaiser A; van den Boom MD; Dokter M; Bendle GM; Haanen JB; Schumacher TN
J Immunol; 2008 Oct; 181(7):5128-36. PubMed ID: 18802117
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
19. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
20. Long-term persistence of CD4(+) but rapid disappearance of CD8(+) T cells expressing an MHC class I-restricted TCR of nanomolar affinity.
Engels B; Chervin AS; Sant AJ; Kranz DM; Schreiber H
Mol Ther; 2012 Mar; 20(3):652-60. PubMed ID: 22233579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
